Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
09:56am, Monday, 07'th Jul 2025
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
2 Soaring Stocks With More Upside Potential to Buy and Hold
08:15am, Friday, 04'th Jul 2025
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends.
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
05:10am, Friday, 04'th Jul 2025
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus
Why Summit Therapeutics Stock Soared 8% Higher Today
03:50pm, Thursday, 03'rd Jul 2025
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
10:56am, Wednesday, 02'nd Jul 2025
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Wednesday, 02'nd Jul 2025
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised
REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
12:26pm, Monday, 23'rd Jun 2025
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Sunday, 22'nd Jun 2025
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
11:54am, Wednesday, 18'th Jun 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Tuesday, 17'th Jun 2025
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
02:45pm, Monday, 16'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:10am, Sunday, 15'th Jun 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:45am, Friday, 13'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors
